CN117069840B - Antibody for specifically detecting IL-21 and application thereof - Google Patents
Antibody for specifically detecting IL-21 and application thereof Download PDFInfo
- Publication number
- CN117069840B CN117069840B CN202311325315.9A CN202311325315A CN117069840B CN 117069840 B CN117069840 B CN 117069840B CN 202311325315 A CN202311325315 A CN 202311325315A CN 117069840 B CN117069840 B CN 117069840B
- Authority
- CN
- China
- Prior art keywords
- antibody
- antigen
- binding fragment
- seq
- antibodies
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 108010074108 interleukin-21 Proteins 0.000 title claims abstract description 67
- 238000002360 preparation method Methods 0.000 claims abstract description 6
- 230000027455 binding Effects 0.000 claims description 36
- 239000012634 fragment Substances 0.000 claims description 36
- 239000000427 antigen Substances 0.000 claims description 35
- 108091007433 antigens Proteins 0.000 claims description 35
- 102000036639 antigens Human genes 0.000 claims description 35
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 18
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims description 10
- 108020004707 nucleic acids Proteins 0.000 claims description 10
- 102000039446 nucleic acids Human genes 0.000 claims description 10
- 150000007523 nucleic acids Chemical class 0.000 claims description 10
- 230000001225 therapeutic effect Effects 0.000 claims description 8
- 239000012620 biological material Substances 0.000 claims description 7
- 229940127121 immunoconjugate Drugs 0.000 claims description 7
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims description 6
- 239000013598 vector Substances 0.000 claims description 6
- 241001465754 Metazoa Species 0.000 claims description 4
- 229960002685 biotin Drugs 0.000 claims description 3
- 235000020958 biotin Nutrition 0.000 claims description 3
- 239000011616 biotin Substances 0.000 claims description 3
- 108090000790 Enzymes Proteins 0.000 claims description 2
- 102000004190 Enzymes Human genes 0.000 claims description 2
- 239000000975 dye Substances 0.000 claims description 2
- 239000007850 fluorescent dye Substances 0.000 claims description 2
- 230000002285 radioactive effect Effects 0.000 claims description 2
- 238000003149 assay kit Methods 0.000 claims 1
- 238000000034 method Methods 0.000 abstract description 25
- 210000004027 cell Anatomy 0.000 abstract description 22
- 238000001514 detection method Methods 0.000 abstract description 22
- 210000000822 natural killer cell Anatomy 0.000 abstract description 9
- 210000001744 T-lymphocyte Anatomy 0.000 abstract description 8
- 102000004127 Cytokines Human genes 0.000 abstract description 5
- 108090000695 Cytokines Proteins 0.000 abstract description 5
- 230000008569 process Effects 0.000 abstract description 5
- 230000009286 beneficial effect Effects 0.000 abstract description 3
- 210000002966 serum Anatomy 0.000 abstract description 3
- 238000002560 therapeutic procedure Methods 0.000 abstract description 3
- 239000001963 growth medium Substances 0.000 abstract description 2
- 238000012827 research and development Methods 0.000 abstract description 2
- 102100030704 Interleukin-21 Human genes 0.000 description 49
- 238000002965 ELISA Methods 0.000 description 14
- 101001010621 Homo sapiens Interleukin-21 Proteins 0.000 description 11
- 239000000243 solution Substances 0.000 description 7
- 102000003812 Interleukin-15 Human genes 0.000 description 6
- 108090000172 Interleukin-15 Proteins 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 238000003118 sandwich ELISA Methods 0.000 description 6
- 239000006228 supernatant Substances 0.000 description 6
- 108010002350 Interleukin-2 Proteins 0.000 description 5
- 102000000588 Interleukin-2 Human genes 0.000 description 5
- 206010028980 Neoplasm Diseases 0.000 description 5
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 5
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 5
- 210000002865 immune cell Anatomy 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 208000023275 Autoimmune disease Diseases 0.000 description 4
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 4
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 4
- 102000003814 Interleukin-10 Human genes 0.000 description 4
- 108090000174 Interleukin-10 Proteins 0.000 description 4
- 108090000978 Interleukin-4 Proteins 0.000 description 4
- 102000004388 Interleukin-4 Human genes 0.000 description 4
- 108090001005 Interleukin-6 Proteins 0.000 description 4
- 102000004889 Interleukin-6 Human genes 0.000 description 4
- 108010002586 Interleukin-7 Proteins 0.000 description 4
- 102000000704 Interleukin-7 Human genes 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 210000004408 hybridoma Anatomy 0.000 description 4
- 230000003472 neutralizing effect Effects 0.000 description 4
- 239000008194 pharmaceutical composition Substances 0.000 description 4
- 238000011357 CAR T-cell therapy Methods 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 230000003915 cell function Effects 0.000 description 3
- 230000007910 cell fusion Effects 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- UQLDLKMNUJERMK-UHFFFAOYSA-L di(octadecanoyloxy)lead Chemical compound [Pb+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O UQLDLKMNUJERMK-UHFFFAOYSA-L 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 230000003053 immunization Effects 0.000 description 3
- 238000002649 immunization Methods 0.000 description 3
- 230000002163 immunogen Effects 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 238000007789 sealing Methods 0.000 description 3
- 230000035945 sensitivity Effects 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000010230 functional analysis Methods 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 238000003018 immunoassay Methods 0.000 description 2
- 238000009169 immunotherapy Methods 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 244000045947 parasite Species 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 239000013600 plasmid vector Substances 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 239000012089 stop solution Substances 0.000 description 2
- 230000000451 tissue damage Effects 0.000 description 2
- 231100000827 tissue damage Toxicity 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 238000013519 translation Methods 0.000 description 2
- 239000013603 viral vector Substances 0.000 description 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 101001043807 Homo sapiens Interleukin-7 Proteins 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 102100037850 Interferon gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- KHGNFPUMBJSZSM-UHFFFAOYSA-N Perforine Natural products COC1=C2CCC(O)C(CCC(C)(C)O)(OC)C2=NC2=C1C=CO2 KHGNFPUMBJSZSM-UHFFFAOYSA-N 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 210000004286 T(FH) Anatomy 0.000 description 1
- 210000000068 Th17 cell Anatomy 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 210000004507 artificial chromosome Anatomy 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000005784 autoimmunity Effects 0.000 description 1
- 239000002981 blocking agent Substances 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 238000002659 cell therapy Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 210000001728 clone cell Anatomy 0.000 description 1
- 238000013373 clone screening Methods 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 230000037029 cross reaction Effects 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000003113 dilution method Methods 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 102000052622 human IL7 Human genes 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000003317 immunochromatography Methods 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 102000008640 interleukin-21 receptor activity proteins Human genes 0.000 description 1
- 108040002099 interleukin-21 receptor activity proteins Proteins 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000008774 maternal effect Effects 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 229930192851 perforin Natural products 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 238000003127 radioimmunoassay Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 239000012898 sample dilution Substances 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
- G01N33/6869—Interleukin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- Pathology (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Peptides Or Proteins (AREA)
Abstract
The invention relates to the technical fields of cell immunology, molecular biology and antibody preparation, in particular to an antibody for specifically detecting IL-21 and application thereof. The antibody for specifically detecting the IL-21 has a special spatial epitope, and shows high affinity and high specificity for the IL-21. The two antibodies provided by the invention are used for the paired antibodies of IL-21, the two antibodies bind different space epitopes, the content of IL-21 in a culture medium and serum can be specifically detected through a double antibody sandwich method, the affinity is high, other cytokines are not bound, and the paired antibodies are ideal detection antibody combinations for the content of IL-21 protein, can be used for researching and developing or producing T cells, NK cells and IL-21 residues in a CAR-T cell process, and are beneficial to accelerating the research and development process of CGT therapy.
Description
Technical Field
The invention relates to the technical fields of cell immunology, molecular biology and antibody preparation, in particular to an antibody for specifically detecting IL-21 and application thereof.
Background
Adoptive immunotherapy with Chimeric Antigen Receptor (CAR) -T cells is a very promising approach to improve prognosis in cancer patients. With the tremendous development and support of technologies, policies and capital and the therapeutic advantages exhibited by the multiple CAR-T products of marketed products, CGT therapy has emerged as an emerging opportunity.
The existing clinical studies show that the expression of a plurality of cytokines is closely related to autoimmune diseases, and besides IL-17, IL-23, tumor necrosis factor TNF-alpha and the like, IL-21 also plays a role in the immunotherapy of a plurality of autoimmune diseases and tumors.
IL-21, interleukin-21 (IL-21), is a four-helix bundle cytokine with a molecular structure similar to IL-15 and is secreted by activated CD4+ T cells, NK cells, tfh cells, and Th17 cells to enhance antigen-specific responses of immune cells. IL-21 induces maturation of NK cells and enhances cytotoxicity. IL-21R is expressed on activated NK cells, inducing killer cells to produce various cytokines such as IFN-gamma, perforin, etc. NK and T cells are T cells involved in autoimmunity, allergy, infection and tumor rejection, and IL-21 and IL-2 or IL-15 can induce proliferation of NK and T cells and have a regulating effect on NK and T cells. Therefore, in the cell culture process in the field of cell therapy, IL-21 is generally added to promote proliferation of cells. Residual detection of IL-21 is a critical element in quality control.
The existing quantitative detection reagent for IL-21 has the problems of unstable method, large inter-plate variation coefficient, interference among different matrixes and the like, and development of an anti-IL-21 antibody with high specificity and high affinity has important significance for realizing efficient and accurate IL-21 detection.
In view of this, the present invention has been made.
Disclosure of Invention
In order to solve the technical problems, the invention provides an antibody for specifically detecting IL-21 and application thereof.
The invention uses HEK293 cell recombinant expressed human IL-21 protein as immunogen to carry out mouse immunity, and obtains hybridoma cell strain for expressing mouse antibody through cell fusion and maternal clone screening and cell subcloning. Experiments prove that the antibody can specifically identify human IL-21 protein, and different matrixes cannot interfere. Further, the invention obtains the amino acid sequence of the antibody and the nucleotide sequence of the encoding gene thereof through hybridoma sequencing.
Based on the findings, the invention provides the following technical scheme:
in a first aspect, the invention provides an antibody or antigen-binding fragment thereof that specifically detects IL-21, said antibody being selected from the following (1) and/or (2):
(1) The amino acid sequences of complementarity determining regions CDR1, CDR2 and CDR3 of the heavy chain variable region are shown in SEQ ID NO: 1. 2 and 3; the amino acid sequences of complementarity determining regions CDR1, CDR2 and CDR3 of the light chain variable region are shown in SEQ ID NO: 4. 5, 6.
SEQ ID NO：1: SYNMN；
SEQ ID NO：2: YIDPYNGGSGYNQKFKG；
SEQ ID NO：3: GDYDGGYYGMDY；
SEQ ID NO：4: RASQSVGTSIH；
SEQ ID NO：5: YASESIS；
SEQ ID NO：6: QQSNGWPFT。
(2) The amino acid sequences of complementarity determining regions CDR1, CDR2 and CDR3 of the heavy chain variable region are shown in SEQ ID NO: 7. 8 and 9; the amino acid sequences of complementarity determining regions CDR1, CDR2 and CDR3 of the light chain variable region are shown in SEQ ID NO: 10. 11, 12.
SEQ ID NO：7: DAWMN；
SEQ ID NO：8: EIRTKTSNHAAYYAASVKG；
SEQ ID NO：9: FDY；
SEQ ID NO：10: RASKNINKHLA；
SEQ ID NO：11: SGSTLQS；
SEQ ID NO：12: QQHNEYPYT。
Preferably, the antibody is selected from the following (1) and/or (2):
(1) Antibody 3G6D7
The amino acid sequence of the heavy chain variable region is:
MEWRWIFLFLLSGTTGVHSEIQLQQSGPELVKPGASVKVSCKASGYGFTSYNMNWVKQSHGKSLEWIGYIDPYNGGSGYNQKFKGKATLTVDKSSSTAYMHLISLTSDDSAVYYCARGDYDGGYYGMDYWGQGTSVTVSS（SEQ ID NO：13）；
the amino acid sequence of the light chain variable region is:
MVSTPQFLVFLLFWIPASRSDILLTQSPAILSVSPGESVSFSCRASQSVGTSIHWFQQRTNGSPRLLIKYASESISGIPSRFSGSGSGTDFTLIINSVESEDIADYYCQQSNGWPFTFGSGTKLEIK（SEQ ID NO：14）。
(2) Antibodies 13A6G6
The amino acid sequence of the heavy chain variable region is:
MYLGLNYVFIVFLLNGVQSEVKLEESGGGLVQPGGSTKLSCAASGFTFSDAWMNWVRQSPEKGLEWIAEIRTKTSNHAAYYAASVKGRFTISRDDSKSSVYLQMNSLRPEDTGIYYCTRFDYWGQGTTLTVSS（SEQ ID NO：15）；
the amino acid sequence of the light chain variable region is:
MRFQVQVLGLLLLWISGAQCDVQITQSPSYLAASPGETITINCRASKNINKHLAWYHDKPGKTNKLLIYSGSTLQSGTPSRFSGSGSGTDFTLTISSLEPEDFAVYYCQQHNEYPYTFGGGTKLAIK（SEQ ID NO：16）。
preferably, the antibody or antigen binding fragment thereof described above is Fab, fab ', F (ab') 2 Fd, fv, dAb, complementarity determining region fragments, single chain antibodies, monoclonal antibodies, animal-derived antibodies, chimeric antibodies, humanized antibodies, bispecific antibodies or multispecific antibodies.
In some embodiments of the invention, an antibody composition is provided, consisting of 3G6D7 and 13A6G6. The two antibodies can be used as paired antibodies of IL-21 and respectively used as coating antibodies and detection antibodies in double-antibody sandwich ELISA. Wherein the detection antibody may also carry a detectable label.
In some embodiments of the invention, an antibody composition is provided, consisting of 3G6D7 and 13A6G6. Wherein, 3G6D7 is used as a coating antibody in double-antibody sandwich ELISA, and 13A6G6 biotin is marked and then used as a detection antibody.
The antibody composition provided by the invention can be used for rapidly detecting the content of the human IL-21 by adopting a double-antibody sandwich ELISA method, and has the advantages of simplicity in operation, high sensitivity, high specificity, high accuracy and high precision.
In a second aspect, the invention provides a nucleic acid molecule encoding an antibody or antigen binding fragment thereof as described above.
Based on the amino acid sequences of the above antibodies or antigen binding fragments thereof, the skilled artisan can obtain nucleotide sequences of nucleic acid molecules encoding the above antibodies or antigen binding fragments thereof. Because of the degeneracy of the codons, the nucleotide sequences of the nucleic acid molecules encoding the antibodies or antigen binding fragments thereof are not unique, and all nucleic acid molecules capable of encoding the production of the antibodies or antigen binding fragments thereof are within the scope of the invention.
In a third aspect, the invention provides a biological material comprising a nucleic acid molecule as described above. Such biological materials include, but are not limited to, recombinant DNA, expression cassettes, transposons, plasmid vectors, viral vectors, engineering bacteria, or transgenic cell lines.
Preferably, the biological material is an expression cassette, vector or host cell.
The above-mentioned expression cassette can be obtained by ligating a transcription or translation regulatory element such as a promoter upstream of the nucleic acid molecule and/or ligating a transcription or translation regulatory element such as a terminator downstream thereof.
Such vectors include, but are not limited to, plasmid vectors, phage vectors, viral vectors, artificial chromosome vectors, and the like.
The host cells include microbial cells, insect cells, or other animal cells.
In a fourth aspect, the present invention provides an antibody conjugate obtained by coupling the antibody or antigen binding fragment thereof to a label selected from one or more of an enzyme label, a biotin label, a fluorescent dye label, a chemiluminescent dye label, and a radioactive label.
In a fifth aspect, the invention provides the use of any of the following (1) - (5) for said antibody or antigen binding fragment thereof or said nucleic acid molecule or said biological material or said antibody conjugate or said antibody composition:
(1) Use in the preparation of a product for detecting the presence or level of IL-21 in a sample;
(2) Use of IL-21 for detecting the presence or level of IL-21 in a sample for non-diagnostic and therapeutic purposes;
(3) Use in the manufacture of a product for detecting immune cell function or therapeutic effect of CAR-T cell therapy;
(4) Use in the preparation of a product for neutralising IL-21 activity in a sample;
(5) Use in the manufacture of a medicament for neutralising IL-21 activity in vivo.
Preferably, the application described in the above (1) or (2) includes: the antibodies or antigen-binding fragments thereof of the invention are prepared as products for detecting the presence or level of IL-21 in a sample, which are used to detect the presence or level of IL-21 in a sample. For ease of detection, the antibodies or antigen-binding fragments thereof of the invention also preferably comprise a detectable label.
The invention also provides methods of detecting the presence or level of IL-21 in a sample, comprising detecting the presence or level of IL-21 in a sample using an antibody or antigen-binding fragment thereof of the invention. The above-described methods may be for diagnostic purposes (e.g., the sample is a sample from a patient, including blood samples, etc.), or for non-diagnostic and therapeutic purposes (e.g., the sample is a culture cell supernatant, etc., not a sample from a patient).
As a method for detecting IL-21 by using the antibody or antigen-binding fragment thereof of the present invention, detection methods such as enzyme-linked immunosorbent assay (ELISA), chemiluminescent immunoassay, radioimmunoassay, fluorescent immunoassay, immunochromatography and the like can be used.
In some embodiments of the invention, IL-21 is detected in a double antibody sandwich method using an antibody or antigen binding fragment thereof of the invention. The double antibody sandwich method is used for detecting IL-21 by using one antibody or antigen binding fragment thereof provided by the invention as a coated antibody, using another antibody or antigen binding fragment thereof provided by the invention as a detection antibody, or using one antibody or antigen binding fragment thereof provided by the invention as a coated antibody, using other known anti-IL-21 antibodies as detection antibodies, or using other known anti-IL-21 antibodies as coated antibodies, and using one antibody or antigen binding fragment thereof provided by the invention as a detection antibody.
In the above (3), the detection of the immune cell function or the therapeutic effect of the CAR-T cell therapy is specifically to determine the immune cell function or the therapeutic effect of the CAR-T cell therapy by detecting the level of IL-21 in the subject. Wherein the immune cells include T cells, NK cells, CAR-T cells, and the like.
In the above (4) and (5), the activity of neutralizing IL-21 is specifically binding to IL-21 in a sample by using the antibody or antigen-binding fragment thereof provided by the present invention, thereby neutralizing the IL-21 activity.
In the above (5), the medicament is used for preventing or treating a disease associated with IL-21 level or a disease mediated by IL-21, including but not limited to tumors, autoimmune diseases and inflammation, immunological pathology and tissue damage caused by parasites, and the like.
Preferably, the IL-21 of the invention is human IL-21.
In a sixth aspect, the invention provides an IL-21 detection kit comprising an antibody or antigen-binding fragment thereof as described above, or comprising an antibody conjugate as described above, or comprising an antibody composition as described above.
In some embodiments of the invention, an ELISA detection kit for IL-21 is provided, said kit comprising an antibody or antigen-binding fragment thereof as described above, or an antibody composition as described above. The kit may also contain other reagents for ELISA detection including, but not limited to, IL-21 standard, PBST wash, blocking solution, chromogenic solution, stop solution, and the like.
In a seventh aspect, the invention provides a pharmaceutical composition comprising an antibody or antigen-binding fragment thereof as described above.
The above pharmaceutical compositions are useful for preventing or treating diseases associated with IL-21 levels or mediated by IL-21, including but not limited to tumors, autoimmune diseases and inflammation, parasite-induced immunological pathologies and tissue damage, and the like. The antibodies or antigen binding fragments thereof provided herein may be used as the sole active ingredient of the pharmaceutical compositions described above, or in combination with other pharmaceutically active ingredients. The pharmaceutical composition may further comprise pharmaceutically acceptable excipients.
In an eighth aspect, the invention provides a method of detecting IL-21 for non-diagnostic and therapeutic purposes, the method comprising: and detecting whether IL-21 and/or the existence level thereof exist in the sample to be detected by using a double-antibody sandwich ELISA method, wherein the coated antibody and the detection antibody in the double-antibody sandwich ELISA method are respectively 3G6D7 and 13A6G6.
Based on the technical scheme, the invention has at least the following advantages and beneficial effects:
the antibody 3G6D7 or the antibody 13A6G6 provided by the invention has special space epitope, and shows high affinity and high specificity to IL-21. The antibody 3G6D7 and the antibody 13A6G6 provided by the invention are jointly used for paired antibodies of IL-21, the two antibodies bind different space epitopes, the content of IL-21 in a culture medium and serum can be specifically detected by a double antibody sandwich method, the affinity is high, and other cytokines (such as IL-2, IL-4, IL-6, IL-7, IL-10, IL-15, GM-CSF, TNF-alpha and the like) are not bound, so that the paired antibodies are ideal antibody combinations for detecting the content of IL-21 protein, can be used for researching and developing or producing T cells, NK cells and IL-21 residues in a CAR-T cell process, and are beneficial to accelerating the research and development process of CGT therapy.
Drawings
In order to more clearly illustrate the technical solutions of the present invention or the prior art, the drawings used in the description of the embodiments or the prior art will be described below.
FIG. 1 is a SDS-PAGE chart showing the process of example 3 of the present invention.
FIG. 2 is a standard curve of the double antibody sandwich quantitative detection of IL-21 in example 3 of the present invention.
Detailed Description
The technical solutions provided by the present invention are described in detail below with reference to examples, but they should not be construed as limiting the scope of the present invention. Unless otherwise indicated, all the experimental procedures used in the examples were conventional; the materials, reagents and the like used are all commercially available.
EXAMPLE 1 preparation of specific human IL-21 antibodies
1. Immunization of mice: human IL-21 protein (available from Acrobiosystems) was used as an immunogen to immunize mice with human IL-21 protein. After the immunization, the immune response level was determined by detecting serum of the immunized animal by ELISA. After the conventional immunization is completed, if the immunized animal can reach the immune response level against the immunogen, cell fusion is performed.
2. Screening: the supernatant of the fused cells was screened by ELISA to select cells positive for the specific binding of human IL-21 protein and devoid of binding to IL-2, IL-4, IL-6, IL-7, IL-10, IL-15, GM-CSF, TNF-alpha protein, etc.
3. Cloning and expanding culture: positive master clone cells were transferred to 24 well plates for expansion culture. Supernatants were collected from each of the expanded clones and tested by ELISA.
4. Subcloning: subcloning positive parent clone by limiting dilution method and subcloning screening by ELISA method.
5. Hybridoma cell antibody gene sequencing: total RNA of the hybridoma cells is extracted, and the RNA is reversely transcribed into cDNA through an RT-PCR reaction. Cloning antibody light chain and heavy chain sequences, constructing the antibody light chain and heavy chain sequences on a T vector, and then carrying out DNA sequencing analysis to obtain antibody gene sequences.
6. Antibody production and purification: and (3) transfecting the antibody gene sequence obtained in the step (5) into HEK293 cells, performing amplification culture, purifying the antibody by adopting a protein A/G affinity chromatography method, and storing the purified antibody in Phosphate Buffer (PBS) by adopting a dialysis method.
EXAMPLE 2 supernatant specific analysis of human IL-21 fused cells
In this example, 10 different cell supernatants were obtained after cell fusion according to example 1, and the human IL-21 antibody was specifically analyzed by ELISA as follows:
1. human IL-21, IL-2, IL-4, IL-6, IL-7, IL-10, IL-15, GM-CSF, TNF-alpha protein was diluted to 1. Mu.g/mL with PBS and added to wells of a microplate with 100. Mu.L per well. The plates were sealed with a plate and left to stand overnight at 4 ℃.
2. The wells were discarded, the ELISA plates were dried, washed with PBST wash solution, 300. Mu.L/Kong Jinpao, and the ELISA plates were dried and washed 3 times.
3. mu.L of blocking agent (PBST wash containing 5% BSA) was added to each well, membrane-sealed with a plate, incubated at 37℃and then washed.
4. The human IL-21 antibody cell supernatant described above was added to the ELISA plate at 100. Mu.L per well. And (5) sealing the plates by using sealing plates, placing the plates at 37 ℃ for incubation, and then cleaning.
5. HRP-Anti-Mouse IgG was diluted to 0.05. Mu.g/mL with sample dilution, 100. Mu.L was added to each well, membrane sealed with sealing plate, incubated at 37℃and washed.
6. The wells were then filled with 100. Mu.L of color development solution, and the wells were covered with a plate membrane, and incubated at 37℃in the absence of light.
7. 50 mu L of stop solution is added into each hole, and the ELISA plate is gently shaken until color development is uniform.
8. The absorbance values of 450 nm and 630nm were read with a microplate reader, and the OD630 value was subtracted with the OD450 to obtain absorbance values (OD values). The absorbance (OD) of each monoclonal antibody is shown in table 1.
TABLE 1 ELISA detection of different antibodies OD values
9. Clones that bound strongly to human IL-21 protein, and that did not bind to IL-2, IL-4, IL-6, IL-7, IL-10, IL-15, GM-CSF, TNF-alpha protein were selected for subcloning. The experimental results showed that of the 8 antibodies, clone numbers 3G6D7, 13A6G6 showed high specificity and no cross-reaction with other mutants.
EXAMPLE 3 analytical identification and functional analysis of antibodies specific for human IL-21
In this example, the human IL-7 specific antibodies screened in example 2 were analyzed for sensitivity by the double antibody sandwich Elisa method and the checkerboard method by methods known in the art, and finally two antibodies IL-21 specific antibodies (Clone: 3G6D7, 13A6G 6) with higher sensitivity were screened out for analytical identification and functional analysis, as follows:
SDS-PAGE identification result (figure 1) shows that the molecular weight of two bands of 3G6D7, 13A6G6 clone number antibody reduction electrophoresis is about 27kDa and 50kDa respectively, and the purity is more than 99%.
The quantitative detection experimental result (figure 2) shows that the antibody of clone numbers 3G6D7 and 13A6G6 can quantitatively detect the human IL-21 by adopting a double antibody sandwich method, so that the protein content in a matrix is obtained, the calculation formula is y= (5.24+0.0089)/[ 1+ (X/110.92) ] -0.97] -0.0089, wherein y is an OD value, the OD value of a sample is brought into the formula, and X is calculated, namely the concentration value of the sample.
The results of quantitative detection of human IL-21 (Table 2) show that quantitative detection of human IL-21 was performed using antibodies to clone numbers 3G6D7, 13A6G6, without interference from the matrix.
TABLE 2 double antibody sandwich assay for recovery of IL-21 in different dilution gradient matrices
The above examples merely represent a few embodiments of the present invention, which facilitate a specific and detailed understanding of the technical solutions of the present invention, but are not to be construed as limiting the scope of the invention. It should be noted that it will be apparent to those skilled in the art that several variations and modifications can be made without departing from the spirit of the invention, which are all within the scope of the invention.
Claims (9)
1. An antibody or antigen-binding fragment thereof that specifically detects IL-21, characterized in that the antibody or antigen-binding fragment thereof is selected from the following (1) or (2):
(1) The amino acid sequences of complementarity determining regions CDR1, CDR2 and CDR3 of the heavy chain variable region are shown in SEQ ID NO: 1. 2 and 3; the amino acid sequences of complementarity determining regions CDR1, CDR2 and CDR3 of the light chain variable region are shown in SEQ ID NO: 4. 5 and 6;
(2) The amino acid sequences of complementarity determining regions CDR1, CDR2 and CDR3 of the heavy chain variable region are shown in SEQ ID NO: 7. 8 and 9; the amino acid sequences of complementarity determining regions CDR1, CDR2 and CDR3 of the light chain variable region are shown in SEQ ID NO: 10. 11, 12.
2. The antibody or antigen-binding fragment thereof according to claim 1, wherein the antibody or antigen-binding fragment thereof is selected from the following (1) or (2):
(1) The amino acid sequence of the heavy chain variable region is shown in SEQ ID NO:13, the amino acid sequence of the light chain variable region is shown in SEQ ID NO: 14;
(2) The amino acid sequence of the heavy chain variable region is shown in SEQ ID NO:15, the amino acid sequence of the light chain variable region is shown in SEQ ID NO: shown at 16.
3. The antibody or antigen-binding fragment thereof according to claim 1 or 2, wherein the antibody or antigen-binding fragment thereof is selected from the group consisting of Fab, fab ', F (ab') 2 Fv, complementarity determining region fragments, single chain antibodies, monoclonal antibodies, animal-derived antibodies, chimeric antibodies, humanized antibodies.
4. A nucleic acid molecule encoding the antibody or antigen-binding fragment thereof of any one of claims 1-3.
5. A biological material comprising the nucleic acid molecule of claim 4; the biological material is an expression cassette, a vector or a host cell.
6. An antibody conjugate, which is characterized in that the antibody or the antigen binding fragment thereof according to any one of claims 1 to 3 is conjugated with a label, wherein the label is one or more selected from the group consisting of an enzyme label, a biotin label, a fluorescent dye label, a chemiluminescent dye label and a radioactive label.
7. Use of an antibody or antigen binding fragment thereof according to any one of claims 1-3 or a nucleic acid molecule according to claim 4 or a biological material according to claim 5 or an antibody conjugate according to claim 6 for the preparation of a product for detecting the presence or level of IL-21 in a sample.
8. Use of the antibody or antigen-binding fragment thereof of any one of claims 1-3 or the antibody conjugate of claim 6 for detecting the presence or level of IL-21 in a sample for non-diagnostic and therapeutic purposes.
9. An IL-21 assay kit comprising the antibody or antigen-binding fragment thereof of any one of claims 1-3, or comprising the antibody conjugate of claim 6.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202311325315.9A CN117069840B (en) | 2023-10-13 | 2023-10-13 | Antibody for specifically detecting IL-21 and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202311325315.9A CN117069840B (en) | 2023-10-13 | 2023-10-13 | Antibody for specifically detecting IL-21 and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN117069840A CN117069840A (en) | 2023-11-17 |
| CN117069840B true CN117069840B (en) | 2024-01-30 |
Family
ID=88717422
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202311325315.9A Active CN117069840B (en) | 2023-10-13 | 2023-10-13 | Antibody for specifically detecting IL-21 and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN117069840B (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109970855A (en) * | 2019-04-12 | 2019-07-05 | 深圳普瑞金生物药业有限公司 | VHH chain of IL23 single domain antibody, IL23 single domain antibody, nucleotide sequence and kit |
| CN112501192A (en) * | 2020-11-20 | 2021-03-16 | 中南大学湘雅二医院 | Hybridoma cell strain for generating anti-human IL21 monoclonal antibody and application thereof |
| CN116554323A (en) * | 2023-04-27 | 2023-08-08 | 中南大学湘雅二医院 | Development and use of humanized anti-IL 21 antibodies |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11267882B2 (en) * | 2016-03-31 | 2022-03-08 | Eli Lilly And Company | Methods of detecting human IL-21 |
| WO2020191316A1 (en) * | 2019-03-21 | 2020-09-24 | Novartis Ag | Car-t cell therapies with enhanced efficacy |
| WO2020219742A1 (en) * | 2019-04-24 | 2020-10-29 | Novartis Ag | Compositions and methods for selective protein degradation |
-
2023
- 2023-10-13 CN CN202311325315.9A patent/CN117069840B/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109970855A (en) * | 2019-04-12 | 2019-07-05 | 深圳普瑞金生物药业有限公司 | VHH chain of IL23 single domain antibody, IL23 single domain antibody, nucleotide sequence and kit |
| CN112501192A (en) * | 2020-11-20 | 2021-03-16 | 中南大学湘雅二医院 | Hybridoma cell strain for generating anti-human IL21 monoclonal antibody and application thereof |
| CN116554323A (en) * | 2023-04-27 | 2023-08-08 | 中南大学湘雅二医院 | Development and use of humanized anti-IL 21 antibodies |
Non-Patent Citations (1)
| Title |
|---|
| AAG35719.1.《GeneBank》.2016,全文. * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN117069840A (en) | 2023-11-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN109937212B (en) | B7-H3 antibody, antigen binding fragment thereof and medical application thereof | |
| EP1415002B1 (en) | Focussed antibody technology | |
| JP2003500015A (en) | Diagnosis and treatment of monoclonal antibodies, antigens and malignancies | |
| AU2010298264B2 (en) | Methods, compositions, and kits for reducing anti-antibody responses | |
| CN116514972B (en) | anti-LAG-3 monoclonal antibody, antigen binding fragment thereof and application thereof | |
| WO2021068761A1 (en) | Humanized monoclonal antibody targeting bcma and having human monkey cross-reactivity | |
| WO2016104439A1 (en) | Anti-active gip antibody | |
| JP2016146820A (en) | Specification method of antigen specific adaptive immune response using arm pcr and high processing sequencing | |
| RU99101121A (en) | POLYEPEPTIDS ABLE TO FORM ANTIGEN-BINDING STRUCTURES SPECIFIC TO RES-D ANTIGENS, DNA ENCODING THEM, METHODS FOR PRODUCING AND APPLICATION | |
| CN112094346B (en) | Monoclonal antibody of mouse anti-cell single-chain transmembrane glycoprotein CD142 capable of being applied to tumor cell capture | |
| CN117069840B (en) | Antibody for specifically detecting IL-21 and application thereof | |
| CN117050178B (en) | Antibody for specifically detecting IL-7 and application thereof | |
| CN117209605B (en) | Antibodies that specifically bind IL-15 and uses thereof | |
| CN116284381B (en) | anti-IFN-gamma antibodies and uses thereof | |
| JP2023515875A (en) | Anti-CD123 Antibodies or Anti-Idiotypic Antibodies that Bind Chimeric Antigen Receptors (CAR) and Methods of Using The Same | |
| JP2022521147A (en) | mRNA display antibody library and method | |
| CN114591427B (en) | Mouse anti-MPT 32 protein hybridoma cell line 13B12, monoclonal antibody based on same and application thereof | |
| CN117164711B (en) | Antibody for resisting neurofilament light chain protein | |
| CN112279917B (en) | Monoclonal antibody of mouse anti-cell surface glycoprotein CD138 capable of being applied to tumor cell capture | |
| CN107286240B (en) | anti-CTRP 4 monoclonal antibody and application thereof | |
| CN117362424A (en) | Helicobacter pylori resistant monoclonal antibody and application thereof | |
| CN114163527A (en) | Nano antibody aiming at toxoplasma clavuligerus protein 5 and coding sequence and application thereof | |
| CN117720650A (en) | Anti-human respiratory syncytial virus antibody and application thereof | |
| CN117720656A (en) | Anti-human interleukin 12P70 antibody and application thereof | |
| CN117720657A (en) | Anti-human interleukin 12P70 antibody and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |